iX Biopharma Ltd.
iX Biopharma Ltd. (42C.SI) Stock Competitors & Peer Comparison
See (42C.SI) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Stock Comparison
42C.SI vs T14.SI Comparison April 2026
42C.SI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 42C.SI stands at 204.5M. In comparison, T14.SI has a market cap of 4.8B. Regarding current trading prices, 42C.SI is priced at SGD 0.20, while T14.SI trades at SGD 3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
42C.SI currently has a P/E ratio of -19.70, whereas T14.SI's P/E ratio is 8.02. In terms of profitability, 42C.SI's ROE is -4.51%, compared to T14.SI's ROE of +0.42%. Regarding short-term risk, 42C.SI is more volatile compared to T14.SI. This indicates potentially higher risk in terms of short-term price fluctuations for 42C.SI.Check T14.SI's competition here